AbbVie v EMA: Humira study reports provide 'roadmap' for competitors
This article was originally published in SRA
Executive Summary
The EU judge who granted interim injunctions preventing the European Medicines Agency from releasing data on AbbVie’s Humira and InterMune’s Esbriet says there are “complex and delicate” questions to be discussed regarding the balance between commercial interests and the public interest. Moreover, he suggests that even when these interests have been properly weighed, it is “not obvious… that the balance will be clearly in favour of the public interest defended by the EMA”1,2.